Novartis AG agreed to buy Medicines Co. for an equity value of about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of acquisitions for Chief Executive Officer Vas Narasimhan.
Medicines Co. shareholders will get $85 a share, Basel, Switzerland-based Novartis said in a statement Sunday. That's a 45 percent premium to the closing price on Nov. 18, before Bloomberg reported the two companies were in talks. The transaction value reaches $9.7 billion on a fully diluted basis that includes outstanding stock options and convertible debt, Novartis said.
The deal brings an experimental cholesterol treatment, inclisiran, into a stable of Novartis products that includes heart-failure medicine Entresto. Novartis's CEO has relied on acquisitions to sharpen the pharma giant's focus on cutting-edge drugs for cancer, rare diseases and other illnesses.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.